Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

599.76 +11.91 (+2.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,317,238
Open 590.93
Bid (Size) 596.10 (1)
Ask (Size) 614.00 (4)
Prev. Close 587.85
Today's Range 586.81 - 601.28
52wk Range 525.99 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield 0.15%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production. 
Via Benzinga
Regeneron Inks Deal With Fujifilm Diosynth Biotechnologies To Increase Manufacturing In US: Retail’s Optimistic
The agreement is to manufacture and supply bulk drug products of Regeneron’s commercial biologic medicines at Fujifilm’s Holly Springs, North Carolina, campus for a period of 10 years. 
Via Stocktwits
Topics Economy Stocks
Exposures Economy US Equities

Performance

YTD
-16.1%
-16.1%
1 Month
-5.4%
-5.4%
3 Month
-13.7%
-13.7%
6 Month
-35.4%
-35.4%
1 Year
-33.8%
-33.8%

More News

Read More
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Discover which S&P500 stocks are making waves on Monday.
Via Chartmill
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion
Via Benzinga
Exposures Product Safety
Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
Via Benzinga
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
These S&P500 stocks are gapping in today's session
Via Chartmill
Is Regeneron Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
Via The Motley Fool
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
In a market where value is scarce, REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
Via Stocktwits
Topics ETFs Government
Exposures COVID-19 Political Product Safety
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
Via Investor's Business Daily

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 599.76
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 04/24/25 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 55.05B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 55B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.